Verve Therapeutics Inc Stock News

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9

BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with...

Equity markets have been volatile this year due to macroeconomic and geopolitical factors. Many of the world's largest corporations haven't escaped the sell-off, and it's hard to predict what's next.

Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (VERV 2.00%) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, according to data compiled by S&P Global Market Intelligence.

VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV's pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly.

Verve Therapeutics (VERV 22.57%) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m.

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort